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Perfluorooctanesulfonate (PFOS) and
perﬂuorooctanoate (PFOA), fully ﬂuorinated
organic compounds, have been widely used in
consumer products (carpets, furniture, house-
hold cleaner, fabrics, and paper products),
and manufacturing processes (industrial sur-
factants and emulsiﬁers). The widespread dis-
tribution and persistence of these compounds
in humans and the environment warrant
study of their potential health impact early in
life when susceptibility may be highest
(Apelberg et al. 2007; Fei et al. 2007). 
PFOA and PFOS cross the placental bar-
rier during pregnancy (Apelberg et al. 2007;
Fei et al. 2007; Inoue et al. 2004; Jin et al.
2004; Midasch et al. 2007; Tittlemier et al.
2004). They are present in cord blood at con-
centrations 1.5–3.5 times lower than those
found in maternal blood (Fei et al. 2007;
Inoue et al. 2004), and they may reduce fetal
growth in animals and humans (Apelberg et al.
2007; Butenhoff et al. 2004; Fei et al. 2007,
2008; Grice et al. 2007; Lau et al. 2006;
Luebker et al. 2005a, 2005b; Thibodeaux et al.
2003). There are no data on their developmen-
tal neurotoxic effects in humans, but exposure
of animals to PFOS or PFOA during preg-
nancy may lead to a decrease in motor func-
tion (Fuentes et al. 2007a, 2007b; Johansson
et al. 2008) and delayed learning (Fuentes
et al. 2007a), as indicated by some animal
studies but not all (Lau et al. 2003). PFOS or
PFOA were also associated with decreased via-
bility, accelerated or delayed sexual matura-
tion, and delays in eye opening and other
developmental end points in rats (Austin et al.
2003; Butenhoff et al. 2004; Lau et al. 2003;
Luebker et al. 2005a, 2005b) or mice (Lau
et al. 2003, 2006). 
In this study we examined exposure to
PFOA or PFOS and neurodevelopmental or
musculoskeletal development using data on
achievement of developmental milestones in
early childhood from the Danish National
Birth Cohort (DNBC) (Olsen et al. 2001).
Materials and Methods
The DNBC recruited women in early preg-
nancy from March 1996 to November 2002
through their general practitioners (GPs)
(Olsen et al. 2001). All pregnant women who
spoke Danish well enough and intended to
carry the pregnancy to term were considered
eligible for the study. Approximately 50% of
GPs took part in the study, and about 60% of
the pregnant women accepted the invitation
from their GPs (Olsen et al. 2001). Study data
were collected by computer-assisted telephone
interviews at approximately 12 and 30 weeks
of gestation, and when children reached
the ages of approximately 6 months and
18 months. Blood samples were drawn from
the mother twice during pregnancy and from
the child (umbilical cord) shortly after birth.
Only blood samples taken in the first
trimester were used in this analysis.
Among 43,045 women who met our
sampling criteria, we randomly selected 1,400
blood samples from the mothers within the
DNBC. PFOA and PFOS concentrations
were analyzed by high-performance liquid
chromatography/tandem mass spectrometry
in the 3M Toxicology Laboratory (St. Paul,
MN, USA). Detailed sampling and labora-
tory methods have been previously published
(Fei et al. 2007). Written informed consent
was obtained from all participants at recruit-
ment, and the Office for Protection of
Research Subjects at University of California,
Los Angeles, and the Danish Data Protection
Agency approved the study protocol. 
We obtained data on Apgar scores by link-
ing cohort members to the National Hospital
Discharge Register (Copenhagen, Denmark)
through use of the unique personal identiﬁca-
tion number assigned to all Danish residents
at birth or immigration. The Apgar score was
recorded as the sum of 0–2 points (in total
0–10 points) from five characteristics (heart
rate, respiratory effort, reﬂex irritability, mus-
cle tone, and skin color) (Apgar 1953).
Midwives assessed Apgar score 5 min after
birth following standardized procedures.
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BACKGROUND: Perﬂuorooctanesulfonate (PFOS) and perﬂuorooctanoate (PFOA) are ﬂuorinated
organic compounds present in the general population at low concentrations. Animal studies have
shown that they may affect neuromuscular development at high concentrations. 
OBJECTIVES: We investigated the association between plasma levels of PFOS and PFOA in preg-
nant women and motor and mental developmental milestones of their children.
METHODS: We randomly selected 1,400 pairs of pregnant women and their children from the
Danish National Birth Cohort. PFOS and PFOA were measured in maternal blood samples taken
in early pregnancy. Apgar score was abstracted from the National Hospital Discharge Register in
Denmark. Developmental milestones were reported by mothers using highly structured question-
naires when the children were around 6 months and 18 months of age. 
RESULTS: Mothers who had higher levels of PFOA and PFOS gave birth to children who had simi-
lar Apgar scores and reached virtually all of the development milestones at the same time as chil-
dren born to mothers with lower exposure levels. Children who were born to mothers with higher
PFOS levels were slightly more likely to start sitting without support at a later age. 
CONCLUSION: We found no convincing associations between developmental milestones in early
childhood and levels of PFOA or PFOS as measured in maternal plasma early in pregnancy.
KEY WORDS: maternal blood, mental developmental milestones, motor developmental milestones,
PFOA, PFOS. Environ Health Perspect 116:1391–1395 (2008). doi:10.1289/ehp.11277 available
via http://dx.doi.org/ [Online 4 June 2008]Motor and mental development of infants at
6 months and 18 months of age was assessed
based on mothers’ self-reports. Mothers were
asked questions developed by an experienced
child neuropsychologist about developmental
milestones within the mental and motor
domains. The motor domains assessed gross
and fine motor functioning. The mental
domains assessed the child’s attention and
cognitive functions, language development,
and social-personal development. For
instance, at the 18-month assessment, nine
questions had a yes/no answer (e.g., “can
he/she take off socks and shoes when you ask
him/her to do so?”). Another three questions
required more detailed responses, including
a) “how old was he/she when he/she could sit
with no support?”; b) “how old was he/she
when he/she could walk with no support?”;
and c) “approximately how many things can
he/she mention by name?”, for which the
mother could choose among five categories
(0–10, 11–25, 26–100, 101–300, and ≥ 300
words), with one additional category of free
text (Olsen et al. 2001). (The questionnaires
are available at http://www.bsmb.dk)
Subjects were divided a priori into four
categories on the basis of quartiles of maternal
PFOA and PFOS exposure during pregnancy.
Logistic regression was used for dichotomized
outcomes. Ordinal logistic regression was
used for outcomes on an ordinal scale (Apgar
score, number of things mentioned by name).
Apgar score was also dichotomized at the cut
point of 10 because of few children with low
values (i.e., only nine infants had Apgar score
< 7, above which is considered in the normal
range, and two infants had Apgar score < 3,
which is considered critically low). 
We used Cox survival models to compare
the age at which the child could sit or walk
without support. The time from birth to the
age when children (in months or in weeks)
started sitting or walking alone was used as the
underlying time variable. We also repeated the
analyses by combining the data on “sitting”
from both postnatal interviews. If their moth-
ers answered “do not know” to the question of
when the child started sitting (n = 82) at the
18-month interview and also reported their
children could not sit at the 6-month inter-
view, we consider these censored (n = 66) at
the 6-month interview. Similar analyses were
repeated for the outcome of when the child
started walking, and those mothers who
answered “do not know” at that time were
treated as censoring events at the 18-month
interview (n = 15). Hazard ratios (HRs) < 1
indicate delayed motor development (e.g., the
child started sitting or walking at a later age).
Maternal age, maternal occupational and
educational status, parity, prepregnancy body
mass index (BMI), smoking and alcohol con-
sumption during pregnancy, gestational
weeks at blood drawing, child’s sex, child’s
age at mother’s interview, breast-feeding after
the child turned 6 months of age (from data
at the 18-month interview), out-of-home day
care (i.e., in day nursery or regular child care),
how many hours the mother spent with the
child every day (assessed at the 18-month
interview), and home density (the total num-
ber of rooms divided by the total number of
persons in the house) were considered as
potential confounders (the categories are pre-
sented in Table 1). Based on prior knowledge
of potential determinants of early childhood
development and/or change-in-estimate prin-
ciples, all mental and motor outcomes, for
consistency, were adjusted for covariates that
satisfied these criteria. In the analyses of
Apgar score, we did not include the following
variables in the model: child’s age at inter-
view, breast-feeding, out-of-home child care,
how many hours the mother spent with the
child every day, and home density. Inclusion
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Table 1. Plasma concentrations of PFOS and PFOA by characteristics of study subjects.
No. (%) PFOS (ng/mL) PFOA (ng/mL)
Characteristica (n = 1,400) (mean ± SD) (mean ± SD)
Maternal age at delivery (years)
< 25 118 (8.4) 38.6 ± 12.0 6.2 ± 2.1
25–29 547 (39.1) 36.8 ± 12.8 6.0 ± 2.8
30–34 504 (36.0) 33.9 ± 13.2 5.2 ± 2.2
≥ 35 230 (16.4) 33.0 ± 12.7 5.1 ± 2.4
Maternal education
Lower 108 (8.0) 36.5 ± 13.3 5.6 ± 2.8
Middle 375 (27.8) 38.4 ± 13.0 5.7 ± 2.4
Higher 866 (64.2) 33.9 ± 12.7 5.5 ± 2.3
Maternal occupation
Manager/professional 227 (16.2) 31.7 ± 12.0 5.3 ± 2.4
Technician 355 (25.4) 35.6 ± 12.8 5.7 ± 2.3
Service/sales worker 478 (34.2) 36.8 ± 12.8 5.7 ± 2.8
Industrial worker 93 (6.6) 39.2 ± 13.7 6.4 ± 2.6
Student 118 (8.4) 34.1 ± 14.6 5.7 ± 2.4
Unemployed 128 (9.2) 33.3 ± 12.1 4.7 ± 2.2
Parity
0 625 (44.7) 37.67 ± 13.04 6.65 ± 2.67
1 508 (36.3) 33.25 ± 12.73 4.75 ± 1.94
≥ 2 266 (19.0) 33.47 ± 12.47 4.65 ± 2.24
Prepregnancy BMI (kg/m2)
< 18.5  58 (4.2) 33.1 ± 14.3 5.2 ± 2.2
18.5–24.9 905 (66.2) 34.6 ± 12.9 5.5 ± 2.6
25.0–29.9  299 (21.9) 36.3 ± 12.0 5.6 ± 2.3
≥ 30.0 105 (7.7) 39.3 ± 14.4 6.1 ± 2.7
Smoking during pregnancy
Nonsmoker 1,052 (75.1) 35.7 ± 13.3 5.6 ± 2.6
Quit smoking 131 (9.4) 33.9 ± 11.6 5.8 ± 2.2
1–9 cigarettes/day 109 (7.8) 35.5 ± 12.7 5.8 ± 2.6
≥ 10 cigarettes/day 108 (7.7) 32.5 ± 11.9 4.9 ± 1.9
Alcohol consumption during pregnancy
Nondrinker  771 (55.79) 35.4 ± 13.1 5.6 ± 2.3
0.5 drinks/week 217 (15.70) 36.2 ± 12.5 5.8 ± 2.5
1–1.5 drinks/week 226 (16.35) 35.2 ± 13.1 5.6 ± 3.3
≥ 2 drinks/week 168 (12.16) 33.4 ± 12.7 5.3 ± 2.4
House density
< 1 room/person 350 (25.0) 31.9 ± 12.2 5.2 ± 2.3
1 room/person 426 (30.5) 36.4 ± 13.4 5.6 ± 2.3
1–1.5 rooms/person 354 (25.3) 36.0 ± 13.5 5.6 ± 2.5
≥ 1.5 rooms/person 269 (19.2) 36.9 ± 12.0 6.0 ± 3.1
Sex
Female 690 (49.3) 35.3 ± 13.0 5.5 ± 2.4
Male 710 (50.7) 35.2 ± 12.9 5.6 ± 2.7
Breast-feeding at child’s age 6 months
Yes 501 (35.8) 34.0 ± 13.1 5.4 ± 2.6
No 898 (64.2) 37.5 ± 12.8 6.0 ± 2.3
How many hours together with mother per day
≤ 1 hr/day 287 (20.5) 35.5 ± 13.5 5.6 ± 2.2
1–4 hr/day 190 (13.6) 37.0 ± 12.2 6.0 ± 2.4
4–5 hr/day 281 (20.1) 35.4 ± 13.7 5.6 ± 2.7
5–7 hr/day 349 (24.9) 35.0 ± 12.8 5.6 ± 2.9
≥ 8 hr/day 292 (20.9) 34.0 ± 12.5 5.2 ± 2.4
Out-of-home child care
Yes 1,229 (87.8) 35.5 ± 13.0 5.7 ± 2.3
No 170 (12.2) 33.7 ± 12.6 5.0 ± 2.6
aMissing data: maternal age (1), maternal education (50), prepregnancy BMI (33), alcohol consumption during pregnancy (18).of gestational age at birth in the multivariate
models did not materially change the esti-
mates of either PFOA or PFOS. Paternal edu-
cation and occupation were also evaluated,
but they did not change the estimates for any
of the outcomes, and therefore were not
included in the ﬁnal models. 
We also restricted our analyses to children
between 5 and 7 months of age at the time of
the 6-month interview (n = 1,336), and chil-
dren between 18 and 20 months of age in the
assessment of the 18-month milestones (n =
1,255). All statistical analyses were performed
using SAS statistical software (version 9.1.3;
SAS Institute Inc., Cary, NC, USA).
Results
Table 1 shows maternal PFOA and PFOS lev-
els according to characteristics of the mothers
and infants. Most of the mothers (90%) were
> 25 years of age at delivery (Table 1), and
almost half of the women were having their
first baby. The levels of maternal PFOS and
PFOA decreased with increasing parity and
with decreasing prepregnancy BMI. Mothers
whose children were being breast-fed at
6 months (36%) had signiﬁcantly lower levels
of PFOA and PFOS during pregnancy. At the
18-month interview, there was no signiﬁcant
difference in average infant age between expo-
sure quartiles, although children in the higher
PFOA group were slightly younger. At the
6-month interview, children whose mothers
had higher PFOA levels were significantly
older than those having lower levels.
In this sample only 0.65% of the new-
borns had an Apgar score < 7 at birth, and
about 93% had an Apgar score equal to 10.
Using ordinal regression did not show any
signiﬁcant association between perﬂuorinated
chemical (PFC) level and Apgar score. When
the dichotomized Apgar score using a cut-
point of 10 was evaluated, the proportion of
newborns with an Apgar score < 10 slightly
increased with increasing PFOA levels, with
5.5% in the first quartile and 8.4% in the
fourth quartile. Similarly, the proportion in
the fourth quartile of PFOS levels (9.8%) was
higher than the lower three quartiles (range,
5.2–7.2%). After adjustment for potential
confounders, none of these associations were
statistically significant; the odds ratio (OR)
for Apgar score < 10 was 1.20 [95% confi-
dence interval (CI), 0.67–2.14] and 1.14
(95% CI, 0.57–2.25) when comparing the
fourth quartile with the ﬁrst quartile of PFOS
and PFOA, respectively. 
At the 18-month interview, the median
age of children was 19.0 months (range,
17–25), and 90% of the children were
between 18 and 20 months. The age at which
children could sit without support ranged
between 3 and 15 months (median = 6), and
the age at which they could walk without sup-
port ranged between 8 and 19 months
(median = 12). No significant associations
were observed between PFOA or PFOS levels
and the age when children could walk (Tables
2 and 3). However, children whose mothers
had higher PFOS levels were more likely to
start sitting without support at a later age; the
adjusted HRs were 0.85 (95% CI, 0.72–0.99)
for the third quartile and 0.86 (95% CI,
0.73–1.01) for the fourth quartile (p for trend
= 0.041) compared with the first quartile.
Results did not change when the mothers
who answered “do not know” were entered as
censored data. 
We observed no association between mater-
nal plasma PFOA or PFOS levels and most of
the outcomes assessed at the 18-month inter-
view. Women with higher PFOS levels, but not
women with higher PFOA levels, were more
likely to have babies who “did not use word-
like sounds to tell what he/she wants” (OR for
the fourth quartile of PFOS versus the first
quartile = 2.93; 95% CI, 1.00–8.56; p for trend
= 0.04). The opposite association with PFOS
levels was observed for the item of “did not use
sentences of two words” (p for trend = 0.05). In
the analysis of “did not make marks on table or
paper,” all the crude ORs for PFOA were above
the null, but the direction was reversed after
adjustment for the potential confounders.
Mutual adjustment for PFOA and PFOS did
not inﬂuence the ORs in any consistent way
(data not shown). The analyses of data from the
6-month interview did not show any associa-
tion between PFC exposure during pregnancy
and motor or mental development. 
Discussion
We observed no convincing association
between levels of PFOA or PFOS as measured
in maternal plasma early in pregnancy and
Perfluorinated chemicals and developmental milestones
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Table 2. HRs and ORs (95% CIs) for developmental milestones at the 18-month interview according to maternal PFOA level (ng/mL) in quartiles.
< LLOQ–3.91 3.91–5.20 5.21–6.96 6.97–41.50
Developmental milestone No. (%) No. (%) HR or OR No. (%) HR or OR No. (%) HR or OR p for trend
Gross motor
Sit without supporta,b (n = 1,318) Reference 0.94 (0.80–1.11) 0.91 (0.77–1.07) 0.89 (0.75–1.06) 0.191
Walk without supporta,b (n = 1,385) Reference 1.10 (0.94–1.28) 1.04 (0.88–1.22) 0.94 (0.80–1.12) 0.326
Did not go up stairs with supportc (n = 1,365) 12 (3.57) 12 (3.49) 1.14 (0.47–2.80) 11 (3.22) 1.09 (0.42–2.80) 11 (3.20) 1.16 (0.42–3.21) 0.814
Fine motorc
Did not take off socks and shoes when  54 (15.61) 62 (17.97) 1.08 (0.70–1.65) 69 (20.00) 1.18 (0.77–1.83) 48 (13.87) 0.68 (0.42–1.11) 0.175
asked to do so (n = 1,381)
Did not drink from an ordinary cup  8 (2.29) 4 (1.15) 0.49 (0.15–1.66) 3 (0.85) 0.37 (0.10–1.40) 4 (1.14) 0.49 (0.15–1.65) 0.183
without helpd(n = 1,399)
Attentionc
Was not occupied alone with the same  60 (17.34) 63 (18.37) 0.85 (0.56–1.29) 62 (17.87) 0.75 (0.49–1.16) 65 (18.79) 0.76 (0.48–1.18) 0.199
thing for at least 15 min (n = 1,381)
Cognitionc
Did not bring things when told tod(n = 1,380) 6 (1.75) 1 (0.29) 0.16 (0.02–1.37) 6 (1.72) 0.98 (0.32–3.09) 3 (0.86) 0.49 (0.12–1.97) 0.637
Did not make marks on table or paper (n = 1,375) 13 (3.74) 21 (6.02) 1.08 (0.50–2.34) 16 (4.58) 0.59 (0.26–1.36) 21 (6.03) 0.57 (0.25–1.32) 0.070
Did not turn the picture right when look  181 (55.02) 169 (51.68) 0.88 (0.64–1.23) 159 (47.32) 0.73 (0.52–1.02) 168 (49.70) 0.82 (0.58–1.17) 0.181
in a book (n = 1,329)
Languagec
Did not use word-like sounds to tell what  11 (3.15) 8 (2.29) 0.65 (0.24–1.77) 7 (1.99) 0.68 (0.23–1.96) 11 (3.14) 1.37 (0.50–3.77) 0.539
he/she wants (n = 1,380)
No. of things he/she can mention  Reference 0.88 (0.64–1.21) 0.86 (0.62–1.20) 0.81 (0.57–1.14) 0.254
by namee (n = 1,397)
Did not use sentences of two words (n = 1,357) 98 (68.53) 93 (61.18) 0.93 (0.67–1.29) 100 (62.11) 0.94 (0.67–1.32) 100 (59.52) 0.80 (0.56–1.14) 0.253
LLOQ, lower limit of quantitation (1 ng/mL). 
aHRs: time to event: the time from birth to the age when children (in months) can start sitting or walking alone. bAdjusted for maternal age, parity, smoking, and alcohol drinking during
pregnancy, maternal education, maternal occupation, prepregnancy BMI, breast-feeding at child’s age 6 months, gestational weeks at blood drawing, out-of-home child care, how
many hours together with mother per day, home density (rooms/person), sex. cAll the same covariates adjusted for the outcome of “sit” and “walk” plus child’s age at interview. dCrude
ORs because of sparse data. eOrdinal logistic regression. motor or mental development in early child-
hood. PFOS was weakly associated with a later
age of being able to sit alone and to “use word-
like sounds to tell what he/she wants,” but no
associations were observed for other end points
in the same domains or with PFOA exposure.
To our knowledge, this is the ﬁrst study to
investigate prenatal PFC exposure and devel-
opmental milestones in humans during the
ﬁrst 18 months of life. We used prospectively
collected data on PFC levels in maternal
plasma drawn early in pregnancy, and the
exposure information was not known at the
time of the interviews. The risk of differential
recall bias is therefore very minimal, but some
nondifferential misclassification is unavoid-
able, although structured questionnaires on
children’s developmental milestones were
administered by specially trained interviewers.
All the milestones are age-dependent, and the
age of the child at interview is therefore a
potential source of bias that we attempted to
avoid by including this variable in the statisti-
cal models. To further examine the extent of
this source of bias, we restricted the analyses to
those 5–6 months of age at the 6-month inter-
view, as well as those 18–20 months of age at
the 18-month interview, and found similar
results to those presented (data not shown).
We used PFC levels measured in maternal
blood early in pregnancy as the measure of
fetal exposure, but it is not clear to what
extent these measures reflect critical fetal
brain exposures throughout pregnancy and in
early childhood. Our data showed PFOS and
PFOA levels in the ﬁrst trimester were highly
correlated with measurements taken in the
second trimester and in cord blood values (Fei
et al. 2007). Children can also be exposed
through breast milk or by contact with prod-
ucts containing PFOA and PFOS. Analyses of
breast milk in Swedish women (Karrman
et al. 2007) showed that breast-milk concen-
tration of PFOS was strongly correlated with
increasing maternal serum concentration, but
PFOA was less frequently detected in breast
milk. Children have been shown to have
higher concentrations of PFOS and PFOA
than adults (Olsen et al. 2003). Our data also
showed that home environment variables,
including house density, number of hours the
mother stayed with the child, and out-of-
home child care were also signiﬁcantly corre-
lated with maternal PFC levels. It is difﬁcult
to predict how PFC exposure in childhood
through breast-feeding or other sources may
have inﬂuenced the results, but residual con-
founding by, or interactions with, childhood
exposure variables cannot be ruled out. 
PFOA and PFOS levels were correlated to
some extent (r = 0.62), but mutual adjustment
did not increase or decrease the ORs in any
consistent way. We presented ORs that were
not mutually adjusted, because this adjustment
is likely to be inappropriate due to multi-
collinearity between the two chemicals.
Similarly, PFOA and PFOS levels were
strongly related to parity in this data set (Fei
et al. 2007), with higher levels observed in
women having their ﬁrst child. Parity therefore
had a strong confounding inﬂuence in our data
set, perhaps reﬂecting the impact of older sib-
lings on various developmental milestones of
younger siblings.
Animal studies have indicated that PFOA
or PFOS may interfere with normal neuro-
muscular development by inhibiting choline
acetyltransferase (ChAT) activity (Johansson
et al. 2008; Lau et al. 2003) or by disturbing
lipid metabolism (U.S. EPA 2006). ChAT
activity is involved in many behavioral phe-
nomena and cognitive functions, but it has
been found slightly reduced only in the pre-
frontal cortex of rat pups exposed in utero to
PFOS, not in the hippocampus (Lau et al.
2003). PFOA is a potent peroxisome prolifer-
ator–activated receptor (PPAR) agonist that
can regulate lipid metabolism in humans.
PPAR-mediated effects on nervous system
structure and function could be another pos-
sible mechanism (U.S. EPA 2006), given the
prevalence of PPAR receptors in the brain.
In conclusion, we found little evidence to
support influence of prenatal PFOA and
PFOS levels on motor or mental developmen-
tal milestones in early childhood at plasma
concentrations that have been reported in the
general population. Because some animal data
show an association, albeit at administered
doses that would result in body burdens
orders of magnitude higher than found in the
general population, a larger study with more
sensitive measures of early childhood develop-
ment would be needed to rule out, with con-
ﬁdence, any subtler adverse effect.
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Table 3. HRs and ORs (95% CIs) for developmental milestones at the 18-month interview according to maternal PFOS level (ng/mL) in quartiles.
6.4–26.0 26.1–33.3 33.4–43.2 43.3–106.7
Developmental milestone No. (%) No. (%) HR or OR No. (%) HR or OR No. (%) HR or OR p for trend
Gross motor
Sit without supporta,b(n = 1,318) Reference 0.93 (0.79–1.08) 0.85 (0.72–0.99) 0.86 (0.73–1.01) 0.041
Walk without supporta,b (n = 1,385) Reference 1.07 (0.92–1.24) 0.99 (0.85–1.15) 0.91 (0.78–1.07) 0.142
Did not go up stairs with supportc (n = 1,365) 15 (4.40) 11 (3.19) 0.71 (0.31–1.65) 6 (1.78) 0.39 (0.14–1.08) 14 (4.09) 0.93 (0.40–2.15) 0.634
Fine motorc
Did not take off socks and shoes  58 (16.71) 60 (17.65) 1.00 (0.66–1.52) 61 (17.48) 0.95 (0.62–1.45) 54 (15.61) 0.82 (0.53–1.27) 0.356
when asked to do so (n = 1,381)
Did not drink from an ordinary cup  6 (1.72) 5 (1.43) 0.83 (0.25–2.75) 4 (1.15) 0.66 (0.18–2.37) 4 (1.14) 0.66 (0.18–2.35) 0.464
without helpd(n = 1,399)
Attentionc
Was not occupied alone with the 55 (15.99) 66 (19.08) 1.13 (0.75–1.69) 66 (19.13) 1.05 (0.69–1.59) 63 (18.16) 0.94 (0.61–1.44) 0.664
same thing for at least 15 min (n = 1,381)
Cognitionc
Did not bring things when told tod(n = 1,380) 4 (1.17) 3 (0.87) 0.74 (0.16–3.34) 3 (0.87) 0.74 (0.16–3.35) 6 (1.73) 1.49 (0.42–5.33) 0.274
Did not make marks on table or  12 (3.46) 14 (4.01) 1.00 (0.44–2.28) 22 (6.32) 1.51 (0.70–3.25) 23 (6.57) 1.21 (0.55–2.67) 0.464
paper (n = 1,375)
Did not turn the picture right when  174 (52.89) 175 (53.19) 1.00 (0.73–1.38) 151 (45.21) 0.71 (0.51–0.98) 177 (52.37) 0.94 (0.68–1.31) 0.345
looking in a book (n = 1,329)
Languagec
Did not use word-like sounds to  6 (1.72) 8 (2.29) 1.39 (0.46–4.25) 9 (2.58) 1.58 (0.51–4.91) 14 (3.98) 2.93 (1.00–8.56) 0.039
tell what he/she wants (n = 1,380)
No. of things he/she can mention  Reference 0.78 (0.57–1.06) 0.98 (0.72–1.35) 0.88 (0.64–1.22)  0.797
by namee(n = 1,397)
Did not use sentences of two  109 (71.71) 90 (59.21) 0.72 (0.52–1.00) 93 (59.24) 0.78 (0.56–1.08) 99 (60.74) 0.68 (0.49–0.95) 0.050
words (n = 1,357)
aHRs: time to event: the time from birth to the age when child (in months) can start sitting or walking alone. bAdjusted for maternal age, parity, smoking and alcohol drinking during preg-
nancy, maternal education, maternal occupation, prepregnancy BMI, breast-feeding at child age 6 months, gestational weeks at blood drawing, out-of-home child care, how many
hours together with mother per day, home density (rooms/person), sex. cAll the same covariates adjusted for the outcome of “sit” and “walk” plus child’s age at interview. dCrude ORs
because of sparse data. eOrdinal logistic regression. REFERENCES
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